Journal
HISTOPATHOLOGY
Volume 80, Issue 1, Pages 109-121Publisher
WILEY
DOI: 10.1111/his.14446
Keywords
bone and soft tissue; genomics; pathology; sarcoma
Categories
Funding
- Sarcoma UK-Sayako Grace Robinson studentship [SGR04.2017]
- Cancer Research UK City of London Clinical Academic Training fellowship
- Cancer Research UK Clinician scientist fellowship [18387]
- University College London Hospital Biomedical Research Centre
- Cancer Research UK Experimental Cancer Centre
Ask authors/readers for more resources
This article reviews recent advances in the diagnosis and treatment of undifferentiated soft tissue sarcoma (USTS), including genomic sequencing, cancer evolution and heterogeneity studies, and immunotherapy. The critical role of pathologists in the diagnosis and treatment of USTS patients is emphasized.
Undifferentiated pleomorphic sarcoma now falls under the broader rubric of undifferentiated soft tissue sarcoma (USTS) in the 2020 World Health Organization classification of bone and soft tissue tumours. These rare cancers remain a diagnosis of exclusion, and show genomic complexity manifesting as extreme forms of aneuploidy and genetic rearrangement. This review covers some of the recent advances in the diagnosis and treatment of USTS based on genomic sequencing, cancer evolution and heterogeneity studies, and immunotherapy. We highlight the critical role that pathologists have to play in the diagnosis and treatment of patients with USTS, viewed through the lens of the hallmarks of cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
